GlassScriptPhysician profile
Catherine Benson
NPI 1548621824
$6,614.88
in general payments reported to CMS, 2019-2025
44 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $1,806 · 2023: $1,622 · 2024: $385 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107 · Consulting Fee: $1,080 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.48 |
| Consulting Fee | $1,080.00 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $1,479.34 | 2022 | |
| Pfizer INC. | $1,143.93 | 2023-2025 | |
| Janssen Biotech, INC. | $689.90 | 2021-2025 | Rybrevant, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $413.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $335.69 | 2021-2025 | Calquence, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $252.43 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Jazz Pharmaceuticals INC. | $179.87 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $168.46 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $160.18 | 2023-2025 | Keytruda, Reblozyl, Lynparza |
| Celgene Corporation | $157.25 | 2022-2025 | Reblozyl |
| Lilly USA, LLC | $142.78 | 2023-2024 | Verzenio |
| Glaxosmithkline, LLC. | $103.60 | 2022 | |
| Seagen INC. | $96.75 | 2023 | Tukysa, Tivdak |
| Alexion Pharmaceuticals, INC. | $89.17 | 2022-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $83.17 | 2023 | Krazati |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $80.93 | 2023-2025 | |
| Abbvie INC. | $72.40 | 2022-2025 | |
| Daiichi Sankyo INC. | $70.02 | 2023-2024 | Injectafer, Enhertu |
| Exelixis INC. | $68.76 | 2022-2023 | Cabometyx |
| Tg Therapeutics, INC. | $63.88 | 2021 | |
| Genentech USA, INC. | $60.20 | 2023-2025 | Tecentriq, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $58.61 | 2022-2023 | Imbruvica |
| Gilead Sciences, INC. | $53.80 | 2022-2023 | |
| Servier Pharmaceuticals LLC | $47.29 | 2023-2025 | |
| Genzyme Corporation | $45.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $44.30 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $41.85 | 2023-2025 | Iclusig |
| Puma Biotechnology, INC. | $40.23 | 2023-2025 | |
| Tersera Therapeutics LLC | $35.64 | 2023-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $31.28 | 2025 | Onivyde |
| Cti Biopharma Corp. | $30.25 | 2023 | Vonjo |
| Eisai INC. | $28.52 | 2025 | |
| Deciphera Pharmaceuticals INC. | $27.48 | 2025 | Qinlock |
| Astellas Pharma US INC | $24.53 | 2022 | |
| G1 Therapeutics, INC. | $23.99 | 2023 | Cosela |
| Nuvation Bio INC. | $23.07 | 2025 | Ibtrozi |
| Adc Therapeutics America, INC. | $21.68 | 2023 | |
| Geron Corporation | $21.35 | 2025 | Rytelo |
| Emd Serono, INC. | $19.97 | 2023 | Bavencio |
| Spectrum Pharmaceuticals INC. | $19.75 | 2025 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $17.49 | 2023 | Rezlidhia, Tavalisse |
| Sumitomo Pharma America, INC. | $16.59 | 2025 | Orgovyx |
| Beigene USA, INC. | $15.57 | 2023 | Brukinsa |
| Azurity Pharmaceuticals, INC. | $13.75 | 2025 | Danziten, Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.